3 withdrawn, 1 terminated. 2 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Withdrawn 2 |
| Phase 2 | 1 | Withdrawn 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Fusilev: new trials by email Literature Review of Fusilev trials Research Report on Fusilev
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab Panitumumab, Oxaliplatin, Leucovorin Calcium - Colorectal Adenocarcinoma, RAS Wild Type | Phase 3 | Terminated | University of Southern California | 4 | 2018-02-27 | 2020-06-11 |
| Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC Irinotecan, Oxaliplatin, Levoleucovorin - Metastatic Colorectal Cancer | Phase 2 | Withdrawn | Fujian Cancer Hospital | 2017-07-20 | 2018-03-27 | |
| Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn® Folotyn, Fusilev - Non-Small Cell Lung Cancer | Phase 1 | Withdrawn | Acrotech Biopharma Inc. | 2013-04-01 | 2020-01-23 | |
| Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn Fusilev, Folotyn - Non Hodgkin's Lymphoma | Phase 1 | Withdrawn | Acrotech Biopharma Inc. | 2013-03-01 | 2020-01-23 |
Colorectal Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Lymphoma, Non-Hodgkin (1)
Acrotech Biopharma Inc. (2) · Fujian Cancer Hospital (1) · University of Southern California (1)
China (1) · United States (1)
Afsaneh Barzi, MD (1) · Ahmed Sawas, MD (1) · Rongbo Lin, MD (1)
P30CA014089 (1)